FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099726276> ?p ?o ?g. }

• W2099726276 endingPage "9" @default.
• W2099726276 startingPage "8393" @default.
• W2099726276 abstract "Failure to control localized prostate cancer can result not only in localized disease progression but also distant metastatic spread. Whereas significant advances in both surgical technique and radiation therapy have improved local control rates with decreased morbidity, consistent long-term control remains elusive. This study investigates the potential of 17-N-allylamino-17-demethoxy geldanamycin (17AAG), a geldanamycin derivative, to sensitize tumor cells to ionizing radiation, permitting a significant improvement to targeted radiotherapies of prostate carcinoma. As a monotherapeutic, 17AAG functions to modulate the action of heat shock protein 90, ultimately affecting a multitude of cellular signaling pathways. It is in Phase I trial and has shown promise in controlling prostate cancer progression. Human prostate tumor cells (LNCaP and CWR22Rv1) were grown as spheroids and incubated for 96 h with increasing doses of 17AAG immediately before and after 2 or 6 Gy low linear energy transfer (LET), high dose-rate irradiation (Cs-137 irradiator). Twelve or 24 spheroids (initial diameter, 150-200 microm) were used per experiment. Response was determined by spheroid volume measurements taken over at least 40 days, after treatment. Incubation of either cell line with 17AAG (<or=1000 nM) or irradiation (<or=6 Gy) alone resulted in transient median growth delays ranging from 2 to 9 days (relative to controls). Combining treatments produced dose- and cell line-dependent supra-additive responses. For LNCaP spheroids, the combination of 2 Gy and 100 nM 17AAG resulted in growth delays additive of the treatments individually; however, increasing either the radiation to 6 Gy or the 17AAG concentration to 1000 nM led to synergistic interactions. Similarly, synergy was noted in CWR22Rv1 studies at only 6 Gy and 1000 nM 17AAG. Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) and Ki67 staining of spheroid sections revealed the increased growth control to be a function of spheroids failing to re-enter the cell cycle. For all 6 Gy experiments, cells remaining from each of the spheroids that failed to regrow were transferred to adherent dishes to evaluate clonogenicity; growth-controlled spheroids also failed to form colonies within 2 weeks of being plated. These results suggest that significant gains in treatment effectiveness may be obtained by combining these treatment modalities, warranting additional preclinical investigation." @default.
• W2099726276 created "2016-06-24" @default.
• W2099726276 creator A5000845600 @default.
• W2099726276 creator A5020652593 @default.
• W2099726276 creator A5031035765 @default.
• W2099726276 creator A5034003269 @default.
• W2099726276 creator A5060228803 @default.
• W2099726276 creator A5072850546 @default.
• W2099726276 creator A5078161354 @default.
• W2099726276 creator A5091101166 @default.
• W2099726276 date "2003-12-01" @default.
• W2099726276 modified "2023-09-23" @default.
• W2099726276 title "Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids." @default.
• W2099726276 cites W1586440254 @default.
• W2099726276 cites W1626426473 @default.
• W2099726276 cites W1665917575 @default.
• W2099726276 cites W1673408032 @default.
• W2099726276 cites W1907894188 @default.
• W2099726276 cites W1956960611 @default.
• W2099726276 cites W1970597172 @default.
• W2099726276 cites W1978844022 @default.
• W2099726276 cites W1981012489 @default.
• W2099726276 cites W1985827132 @default.
• W2099726276 cites W1989494625 @default.
• W2099726276 cites W1990287298 @default.
• W2099726276 cites W1999938778 @default.
• W2099726276 cites W2004792969 @default.
• W2099726276 cites W2018600927 @default.
• W2099726276 cites W2022725205 @default.
• W2099726276 cites W2025027678 @default.
• W2099726276 cites W2026438770 @default.
• W2099726276 cites W2044032707 @default.
• W2099726276 cites W2046329541 @default.
• W2099726276 cites W2058507321 @default.
• W2099726276 cites W2067125737 @default.
• W2099726276 cites W2069173248 @default.
• W2099726276 cites W2095705375 @default.
• W2099726276 cites W2098301610 @default.
• W2099726276 cites W2103429819 @default.
• W2099726276 cites W2124705172 @default.
• W2099726276 cites W2138302361 @default.
• W2099726276 cites W2146421906 @default.
• W2099726276 cites W2148180201 @default.
• W2099726276 cites W2149884878 @default.
• W2099726276 cites W2154369685 @default.
• W2099726276 cites W2156095111 @default.
• W2099726276 cites W2323637689 @default.
• W2099726276 cites W2324567856 @default.
• W2099726276 cites W2465489203 @default.
• W2099726276 cites W3021368244 @default.
• W2099726276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14679001" @default.
• W2099726276 hasPublicationYear "2003" @default.
• W2099726276 type Work @default.
• W2099726276 sameAs 2099726276 @default.
• W2099726276 citedByCount "15" @default.
• W2099726276 countsByYear W20997262762012 @default.
• W2099726276 countsByYear W20997262762013 @default.
• W2099726276 countsByYear W20997262762016 @default.
• W2099726276 countsByYear W20997262762017 @default.
• W2099726276 countsByYear W20997262762018 @default.
• W2099726276 countsByYear W20997262762019 @default.
• W2099726276 countsByYear W20997262762021 @default.
• W2099726276 countsByYear W20997262762022 @default.
• W2099726276 crossrefType "journal-article" @default.
• W2099726276 hasAuthorship W2099726276A5000845600 @default.
• W2099726276 hasAuthorship W2099726276A5020652593 @default.
• W2099726276 hasAuthorship W2099726276A5031035765 @default.
• W2099726276 hasAuthorship W2099726276A5034003269 @default.
• W2099726276 hasAuthorship W2099726276A5060228803 @default.
• W2099726276 hasAuthorship W2099726276A5072850546 @default.
• W2099726276 hasAuthorship W2099726276A5078161354 @default.
• W2099726276 hasAuthorship W2099726276A5091101166 @default.
• W2099726276 hasConcept C104317684 @default.
• W2099726276 hasConcept C111337013 @default.
• W2099726276 hasConcept C121332964 @default.
• W2099726276 hasConcept C121608353 @default.
• W2099726276 hasConcept C126322002 @default.
• W2099726276 hasConcept C175369904 @default.
• W2099726276 hasConcept C18231593 @default.
• W2099726276 hasConcept C185544564 @default.
• W2099726276 hasConcept C185592680 @default.
• W2099726276 hasConcept C202751555 @default.
• W2099726276 hasConcept C205260736 @default.
• W2099726276 hasConcept C2775932338 @default.
• W2099726276 hasConcept C2776235491 @default.
• W2099726276 hasConcept C2779707156 @default.
• W2099726276 hasConcept C2779723316 @default.
• W2099726276 hasConcept C2780192828 @default.
• W2099726276 hasConcept C2780297055 @default.
• W2099726276 hasConcept C502942594 @default.
• W2099726276 hasConcept C55493867 @default.
• W2099726276 hasConcept C62112901 @default.
• W2099726276 hasConcept C71924100 @default.
• W2099726276 hasConceptScore W2099726276C104317684 @default.
• W2099726276 hasConceptScore W2099726276C111337013 @default.
• W2099726276 hasConceptScore W2099726276C121332964 @default.
• W2099726276 hasConceptScore W2099726276C121608353 @default.
• W2099726276 hasConceptScore W2099726276C126322002 @default.

• next